These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22088930)

  • 1. Frequency of hospitalization and severe events in 497 spondylarthritis patients treated with anti-TNF drugs: comparisons with 423 RA patients.
    Gérard-Benoist S; Leux C; Le Goff B; Maugars Y; Berthelot JM
    Joint Bone Spine; 2012 Mar; 79(2):204-5. PubMed ID: 22088930
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
    Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
    Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
    J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sporotrichoid non-tuberculous mycobacterial infections following anti-TNF treatment.
    Doudier B; Quiles-Tsimaratos N; Arniaud D
    Med Mal Infect; 2018 May; 48(3):222-225. PubMed ID: 29331451
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.
    Vincent FB; Pavy S; Krzysiek R; Lequerré T; Sellam J; Taoufik Y; Mariette X; Miceli-Richard C
    Joint Bone Spine; 2016 Oct; 83(5):595-7. PubMed ID: 27066773
    [No Abstract]   [Full Text] [Related]  

  • 6. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion.
    DI Franco M; Paradiso M; Ceccarelli F; Scrivo R; Spinelli FR; Iannuccelli C; Valesini G
    J Rheumatol; 2012 Jan; 39(1):41-5. PubMed ID: 22045840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse effects of TNF inhibitors in SpA: are they different from RA?
    Sampaio-Barros PD; van der Horst-Bruinsma IE
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):747-63. PubMed ID: 25488782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.
    Scirè CA; Caporali R; Sarzi-Puttini P; Frediani B; Di Franco M; Tincani A; Sinigaglia L; Sfriso P; Tirri R; Bellis E; Delsante G; Porru G; Salaffi F; Giuggioli D; Rossini M; Todoerti M; Bazzichi L; Govoni M; Gerli R; Raschetti R; Minisola G; Montecucco C; Todesco S;
    Clin Exp Rheumatol; 2013; 31(6):857-63. PubMed ID: 23981363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: a population-based study.
    Machado MA; Bernatsky S; Bessette L; Nedjar H; Rahme E
    BMC Musculoskelet Disord; 2016 Jul; 17():298. PubMed ID: 27431503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden.
    Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
    Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1399-406. PubMed ID: 20506121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulphasalazine lung toxicity: report of two cases.
    Karmakar GC; Wong CA; Horwood F; Anderson G
    N Z Med J; 2010 Aug; 123(1320):86-7. PubMed ID: 20720607
    [No Abstract]   [Full Text] [Related]  

  • 12. Rheumatoid Arthritis - Anti-TNF.
    Chaabo K; Kirkham B
    Int Immunopharmacol; 2015 Aug; 27(2):180-4. PubMed ID: 25962818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.
    Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
    Ann Rheum Dis; 2010 Feb; 69(2):352-7. PubMed ID: 19282310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent.
    Koo BS; Hong S; Kim YJ; Kim YG; Lee CK; Yoo B
    Korean J Intern Med; 2015 Jan; 30(1):104-9. PubMed ID: 25589842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of anti-TNF-alpha therapy on the nature of service provision.
    Armstrong DJ; McCausland EM; Wright GD
    Rheumatology (Oxford); 2006 Jan; 45(1):112. PubMed ID: 16278287
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluating the real-world benefits and risks of anti-tumor necrosis factor therapies.
    Low A; Hyrich K
    J Rheumatol; 2013 Jan; 40(1):4-6. PubMed ID: 23280161
    [No Abstract]   [Full Text] [Related]  

  • 18. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current status of therapeutic approaches in spondyloarthropathies].
    Sieper J; Braun J
    Z Rheumatol; 2001 Dec; 60(6):458-63. PubMed ID: 11826741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNFs in axial spondyloarthritis.
    Kocijan R; Muschitz C; Rech J
    Wien Med Wochenschr; 2015 Jan; 165(1-2):10-3. PubMed ID: 25572548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.